Beta-Thalassemia Condition, Symptoms and Treatment

For your adult patients with
transfusion-dependent β-thalassemia

With Reblozyl—the first and only erythroid maturation
agent—you can reduce patients’ red blood cell (RBC) transfusion burden.^1-4

Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anemia associated with beta-thalassemia.¹

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See Section 4.8 in the EU Summary of Product Characteristics for more information. Before prescribing Reblozyl, please refer to the EU Summary of Product Characteristics.

References:

1. Reblozyl^® (luspatercept) Summary of Product Characteristics (SmPC). Celgene 2020.

2. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408-414.

3. Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766-770.

4. Musallam KM, Rivella S, Vichinsky E, et al. Non-transfusion-dependent thalassemias. Hematologica. 2013;98(6):833-844.

This site is not intended for US or UK healthcare professionals.